Acetylcholinesterase inhibitors are widely prescribed to patients with mild to moderate Alzheimer's disease (AD), with studies showing they improve cognition and stabilize cognition, function and behaviour for up to 6–12 months (see below). This evidence concerns the gene ACHE and Alzheimer disease.